Akebia Therapeutics, Inc. (AKBA) Announces Earnings Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.36, Bloomberg Earnings reports. The company had revenue of $28.52 million during the quarter, compared to analysts’ expectations of $26.50 million.

Shares of Akebia Therapeutics (NASDAQ:AKBA) opened at 13.95 on Thursday. The stock has a 50 day moving average of $14.19 and a 200-day moving average of $11.82. The company’s market capitalization is $255.29 million. Akebia Therapeutics has a one year low of $7.16 and a one year high of $16.54.

COPYRIGHT VIOLATION NOTICE: “Akebia Therapeutics, Inc. (AKBA) Announces Earnings Results” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2017/08/10/akebia-therapeutics-inc-akba-announces-earnings-results.html.

In other Akebia Therapeutics news, Director Muneer A. Satter bought 1,034,482 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was purchased at an average cost of $14.50 per share, with a total value of $14,999,989.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.95% of the company’s stock.

A number of brokerages have recently weighed in on AKBA. UBS AG restated a “buy” rating and issued a $17.00 price objective (up from $12.00) on shares of Akebia Therapeutics in a report on Friday, May 5th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Akebia Therapeutics in a report on Tuesday, June 6th. Needham & Company LLC restated a “buy” rating and issued a $21.00 price objective (up from $18.00) on shares of Akebia Therapeutics in a report on Wednesday, May 17th. JMP Securities boosted their price objective on shares of Akebia Therapeutics from $19.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, April 26th. Finally, Zacks Investment Research lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. Akebia Therapeutics currently has an average rating of “Buy” and an average target price of $19.71.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply